Jorge Ibarra
Family · El Paso, TXNPI 1457776882
Payments from drug & device makers
Across 554 payments — averaging $20.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- Lilly USA, LLC$1K
- Abbott$1K
- Amgen$978
- Pfizer$820
- Novo Nordisk$809
- plus $5K from 29 others
What the payments were for
- Travel & lodging$3984%
- Food & beverage$10,83296%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 35 | $1,313 |
| Lilly USA, LLC | 91 | $1,301 |
| Abbott | 49 | $1,094 |
| Amgen | 41 | $978 |
| Pfizer | 51 | $820 |
| Novo Nordisk | 35 | $809 |
| AbbVie | 36 | $591 |
| Bayer | 32 | $518 |
| Sanofi-aventis U.S. LLC | 15 | $514 |
| Boehringer Ingelheim | 28 | $433 |
| Medtronic | 4 | $398 |
| Biohaven Pharmaceuticals, Inc. | 21 | $384 |
| Biohaven Pharmaceutical Holding Company Ltd. | 16 | $278 |
| Amarin Pharma, Inc. | 12 | $204 |
| Johnson & Johnson | 11 | $190 |
| Scilex Pharmaceuticals Inc. | 9 | $185 |
| GSK | 10 | $173 |
| Astellas Pharma US Inc | 8 | $165 |
| Ardelyx, Inc. | 6 | $162 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 9 | $141 |
| Merck | 9 | $135 |
| Novartis | 5 | $95 |
| Inspire Medical Systems, Inc. | 2 | $77 |
| Kowa Pharmaceuticals America, Inc. | 4 | $51 |
| Phathom Pharmaceuticals, Inc. | 3 | $47 |
| Smith+Nephew | 2 | $33 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $23 |
| Mannkind Corporation | 2 | $22 |
| E.r. Squibb & Sons, L.L.C. | 1 | $19 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $19 |
| Antares Pharma, Inc. | 1 | $17 |
| Radius Health, Inc. | 1 | $15 |
| Exact Sciences | 1 | $15 |
| Dexcom, Inc. | 1 | $13 |
| Inogen, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$630
- AIRSUPRA$399
- BREZTRI$375
- CD HORIZON$338
- FREESTYLE LIBRE 3$268
- Repatha$251
- Ozempic$244
- SOLIQUA 100/33$211
- Otezla$125
- Kerendia$125
- TOUJEO$123
How this compares
$11,242 in reported general payments places this provider in the 95th percentile of 15,456 family providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 84 | $142,556 |
| FarxigaDapagliflozin Propanediol | 111 | $128,223 |
| MounjaroTirzepatide | 62 | $124,495 |
| TrulicityDulaglutide | 45 | $84,048 |
| JardianceEmpagliflozin | 37 | $53,046 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 26 | $38,423 |
| RybelsusSemaglutide | 14 | $36,730 |
| JanuviaSitagliptin Phosphate | 23 | $30,221 |
| LinzessLinaclotide | 22 | $22,220 |
| VascepaIcosapent Ethyl | 21 | $18,560 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 15 | $15,122 |
| Repatha SureclickEvolocumab | 17 | $13,367 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 15 | $11,919 |
| Omega-3 Acid Ethyl Esters | 41 | $6,719 |
| DapagliflozinDapagliflozin Propanediol | 11 | $5,861 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $1,301 | $208,542107 claims |
| Novo NordiskOzempic, Rybelsus | $809 | $179,28698 claims |
| AstraZenecaFarxiga | $1,313 | $128,223111 claims |
| Boehringer IngelheimJardiance | $433 | $53,04637 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $514 | $38,42326 claims |
| MerckJanuvia | $135 | $30,22123 claims |
| AbbVieLinzess | $591 | $22,22022 claims |
| GSKTrelegy Ellipta | $173 | $15,12215 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 15,456 family providers in Texas.
Other family in El Paso
- Margarita FavelaEl Paso$73K
- Lashonda CraneHouston$3.4M
- David WeirDallas$959K
- Luba YammineHouston$479K
- Robin BeachHouston$428K
- Nirupama JeromeAustin$418K
- April LopezMcAllen$417K
- Linda MercadoHouston$211K
- Sarah AguilarHouston$199K
- Sie ThomasDallas$197K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.